On 30 October 2019 the Chief Pharmaceutical Inspectorate granted a new Manufacturing Authorisation for F1 Pharma S.A.
As a result of the transformation of F1 Pharma into a joint stock company, we submitted a request to the Chief Pharmaceutical Inspectorate for the amendment of our Manufacturing Authorisation. The Chief Pharmaceutical Inspectorate accepted the requested amendment and on 30/10/2019 issued a decision granting new authorisation for F1 Pharma S.A.
The extent of our authorization remains unchanged. You can view the new authorization here.